# Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia

> **NCT03628053** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel
- **DRUG:** Blinatumomab
- **DRUG:** Inotuzumab

## Key facts

- **NCT ID:** NCT03628053
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-05
- **Primary completion:** 2025-10-08
- **Final completion:** 2026-01-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies in this patient population.
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628053, "Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03628053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*